Aurobindo Upbeat On Outlook As It Moves To Close Sandoz Deal
Executive Summary
India's Aurobindo says it is betting its $1bn purchase of Sandoz' US dermatology assets will help “really fuel growth” and that the company's biggest acquisition should be wrapped up in eight to 12 weeks.
You may also be interested in...
Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate
While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.
Aceto Claims Aurobindo Caused Its Collapse
Aceto has blamed Aurobindo for its downfall, alleging a series of calculated and deceitful actions that have critically wounded the US group’s pharma business. Aurobindo has strongly denied the charges.
Slowing Biopharmaceuticals Puts A Dent In Sandoz’ Sales
Slower sales growth by its Biopharmaceuticals unit amid competitive pressures in the US, combined with weakness in its Retail Generics and Anti-Infectives franchises, led Sandoz to report an overall 8% sales slide in the first quarter of this year.